Important Safety Information Prescribing Information Patient Site

A non-dispensing pharmacy that simplifies the prescribing process by finding the right partner for patients' health care coverage

Choose YcanthRx™ Pharmacy in your EMR

To ePrescribe

Find YcanthRx Pharmacy in the pharmacy search of your EMR:

YcanthRx Pharmacy 15058 Beltway Drive, Suite 119A Addison, TX 75001
NCPDP: 5948243 NPI: 1114837911
Phone: (855) 922-6847 Fax: (844) 922-6847

YCANTH is a specialty pharmacy medication.
Patient-labeled YCANTH ships directly to your office, clinic or hospital for administration.


Call (855) 922-6847

How to Load Your EMR

YCANTH® Prescribing Information

NDC 71349-070-01
Days Supply 21
Indication YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older
Dosage Form Topical Application
Prescription Form Topical solution 0.7%: Each mL of YCANTH contains 7 mg (0.7%) of cantharidin in a light violet to dark purple, slightly viscous liquid
SIG Apply topically to affected area every 3 weeks as needed
Dispense Quantity 2 (Single Use Applicators), up to 3 refills†
Dispense Unit EA
Specialty Pharmacy (In EHR, search by Zip code and in "ALL Pharmacies" database) YcanthRx Pharmacy
15058 Beltway Drive, Suite 119A
Addison, TX 75001
Notes to Pharmacy*
  • Patient's PBM and Medical Insurance Carrier Names and Member ID#s
  • Previously Tried/Failed Treatments if applicable
  • Include Relevant Clinical Notes
Important Information to include on Prescription
  • Patient/Caregiver Phone # and Address
  • Diagnosis Code (ICD-10: B08.1)

* Important note: Send Patient Insurance and Clinical Information to YcanthRx with eRx via e-fax or other applicable method within EHR to expedite Prior Authorization process

†When medically indicated

Download eRx Instructions

YCANTH Application Training

YCANTH must be administered by a trained healthcare provider.

Get trained or a refresher on YCANTH applicator best practices before treating with YCANTH.

Go to YCANTH Virtual Training Go to Applicator Best Practices

Need Help?

Call YcanthRx Support at (855) 922-6847

Hours of Operation: Monday‑Friday, 8AM‑8PM ET

You are about to leave the YCANTHPro.com website by opening a new webpage. The site you are linking to is not controlled by Verrica Pharmaceuticals and we are not responsible for the content presented on that site.

Thank you for visiting YCANTHPro.com.

Leave site

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.

INDICATION

YCANTH (cantharidin) topical solution, 0.7% is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.
  • Local Skin Reactions: Reactions at the application site may occur, including vesiculation, pruritus, pain, discoloration, and erythema. Avoid application near eyes and mucosal tissue, and to healthy skin. If YCANTH contacts any unintended surface, or healthy skin, immediately remove. If severe local skin reactions occur, remove prior to the recommended 24 hours after treatment.
  • YCANTH is flammable, even after drying. Avoid fire, flame or smoking near lesion(s) during treatment and after application until removed.

ADVERSE REACTIONS:

The most common (incidence ≥1%) reactions are the following local skin reactions at the application site: vesiculation, pain, pruritus, scabbing, erythema, discoloration, application site dryness, edema, and erosion. Local skin reactions at the application site were observed in 97% of subjects treated with YCANTH during clinical trials. These local skin reactions are expected and related to the anticipated blistering response of the skin to cantharidin.

DRUG INTERACTIONS:

No studies evaluating the drug interaction potential of cantharidin have been conducted.

USE IN SPECIFIC POPULATIONS:

Pregnancy: There are no available data with use of YCANTH in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Given that systemic exposure to cantharidin following topical administration is low, maternal use is not expected to result in fetal exposure to the drug.

Lactation: Avoid application of YCANTH topical solution to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child.

OVERDOSAGE:

Oral ingestion of cantharidin has resulted in renal failure, blistering and severe damage to the gastrointestinal tract, coagulopathy, seizures, and flaccid paralysis.

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Verrica Pharmaceuticals Inc. at 1-877-VERRICA (1-877-837-7422), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Local skin reactions are expected and should be reported if they are severe.